Title: Intellectual property rights and innovation
Description: "The NBER Bulletin on Aging and Health provides summaries of publications like this.  You can sign up to receive the NBER Bulletin on Aging and Health by email.  This paper provides empirical evidence on how intellectual property (IP) on a given technology affects subsequent innovation.  To shed light on this question, I analyze the sequencing of the human genome by the public Human Genome Project and the private firm Celera, and estimate the impact of Celera's gene-level IP on subsequent scientific research and product development outcomes.  Celera's IP applied to genes sequenced first by Celera, and was removed when the public effort re-sequenced those genes.  I test whether genes that ever had Celera's IP differ in subsequent innovation, as of 2009, from genes sequenced by the public effort over the same time period, a comparison group that appears balanced on ex ante gene-level observables.  A complementary panel analysis traces the effects of removal of Celera's IP on within-gene flow measures of subsequent innovation.  Both analyses suggest Celera's IP led to reductions in subsequent scientific research and product development outcomes on the order of 30 percent.  Celera's short-term IP thus appears to have had persistent negative effects on subsequent innovation relative to a counterfactual of Celera genes having always been in the public domain"--National Bureau of Economic Research web site.